Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

NCT03287960 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Leptin Receptor Deficiency Obesity

Interventions

DRUG: Setmelanotide
DRUG: Placebo

Sponsor

Rhythm Pharmaceuticals, Inc.